D

id the Food and Drug Administration treat Amgen (AMGN) differently than Johnson & Johnson (JNJ) when reviewing applications for their drugs?

A federal judge ruled late last week that the agency, in fact, may have acted inconsistently when it denied pediatric exclusivity for a blockbuster Amgen drug and ordered the FDA to explain its reasoning. The ruling could mean that Amgen may eventually win six months of pediatric exclusivity, which would allow the company to forestall generic competition to a best-selling drug.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Given the current battles over “abuse” of orphan drug and pediatric exclusivity to support exorbidant (ok, high) prices, I have some sympathy for the FDAs position.) We’ll see how the case plays out.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.